Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00788125 · FLOW

Participant flow

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors · Source last updated 2023-07-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    35 mg/m\^2/dose BID PO Dasatinib x 17 days Ifosfamide, Carboplatin, Etoposide microarray analysis western blotting immunohistochemistry staining method laboratory biomarker analysis therapeutic conventional surgery radiation therapy
    id
    FG000
    title
    Period 1: 35 mg/m^2 Dasatinib BID PO
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        6
      type
      Death
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        7
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        1
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        6
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Phase I of this study involved City of Hope patients, only. This protocol did not progress beyond Period 1: 35 mg/m\^2/dose BID to other dose levels within Phase I. This protocol did not progress to Phase II, which would have involved other institutions. Sponsor withdrew support.
recruitment Details
Phase I study participants were recruited based on physician referral at City of Hope Medical Center, between September 04, 2008 and February 04, 2010. Seven patients met the inclusion criteria and were enrolled on the study.
Complete source fields
groups
  1. description
    35 mg/m\^2/dose BID PO Dasatinib x 17 days Ifosfamide, Carboplatin, Etoposide microarray analysis western blotting immunohistochemistry staining method laboratory biomarker analysis therapeutic conventional surgery radiation therapy
    id
    FG000
    title
    Period 1: 35 mg/m^2 Dasatinib BID PO
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        6
      type
      Death
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        7
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        1
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        6
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Phase I of this study involved City of Hope patients, only. This protocol did not progress beyond Period 1: 35 mg/m\^2/dose BID to other dose levels within Phase I. This protocol did not progress to Phase II, which would have involved other institutions. Sponsor withdrew support.
recruitment Details
Phase I study participants were recruited based on physician referral at City of Hope Medical Center, between September 04, 2008 and February 04, 2010. Seven patients met the inclusion criteria and were enrolled on the study.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice